Active substance
Cefuroxime
- SFDA 51
- US FDA 43
- Health Canada 9
- US price lines 2
- NHS prices 1
- WHO EML 1
- Safety 5
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CEFOFIX 750 MG VIALS | 750 mg | Solution for infusion · Parenteral use | 1 Vial | SAR 11.00 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| CEFOVEX 500MG TABLET | 500 mg | Tablet · Oral use | 10 Blister | SAR 49.30 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| CEFUREX 125MG-5ML POWDER FOR SUSPENSION | 25 mg/ml | Powder for suspension · Oral use | 1 Bottle | SAR 18.50 | Generic · Prescription | Middle East Pharmaceutical and Chemical Industries and Medical Appliances Co. | Valid |
| CEFUREX 250MG F-C TABLETS | 250 mg | Film-coated tablet · Oral use | 10 Blister | SAR 20.80 | Generic · Prescription | Middle East Pharmaceutical and Chemical Industries and Medical Appliances Co. | Valid |
| CEFUREX 250MG-5ML POWDER FOR SUSPENSION | 50 mg/ml | Powder for suspension · Oral use | 1 Bottle | SAR 27.45 | Generic · Prescription | Middle East Pharmaceutical and Chemical Industries and Medical Appliances Co. | Valid |
| CEFUREX 500MG F-C TABLETS | 500 mg | Film-coated tablet · Oral use | 10 Blister | SAR 34.05 | Generic · Prescription | Middle East Pharmaceutical and Chemical Industries and Medical Appliances Co. | Valid |
| CEFUTIL 250MG F.C TABLET | 250 mg | Film-coated tablet · Oral use | 10 Blister | SAR 23.50 | Generic · Prescription | Pharma International Co. | Valid |
| CEFUTIL 500 MG TABLETS | 500 mg | Film-coated tablet · Oral use | 10 Blister | SAR 36.05 | Generic · Prescription | Pharma International Co. | Valid |
| CEFUZIME 125MG-5ML POWDER FOR ORAL SUSP | 25 mg/ml | Powder for oral suspension · Oral use | 1 Bottle | SAR 23.15 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| CEFUZIME 500 MG TAB | 500 mg | Film-coated tablet · Oral use | 10 Blister | SAR 63.95 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| CEFUZIME 750 MG INJECTION,I.M - I.V VIAL | 750 mg | Powder for injection · Parenteral use | 1 Vial | SAR 7.50 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| CERUXIM 1.5 g powder for solution for injection or infusion | 1.5 g | powder for solution for injection · Parenteral use | 10 Vial | SAR 134.20 | Generic · Prescription | MEDOCHEMIE LTD PHARMACEUTICAL INDUSTRY | Valid |
| CERUXIM 250 mg Film Coted Tablet | 250 mg | Film-coated tablet · Oral use | 20 Strip | SAR 33.70 | Generic · Prescription | MEDOCHEMIE LTD PHARMACEUTICAL INDUSTRY | Valid |
| CERUXIM 500 mg Film Coted Tablet | 500 mg | Film-coated tablet · Oral use | 20 Strip | SAR 56.55 | Generic · Prescription | MEDOCHEMIE LTD PHARMACEUTICAL INDUSTRY | Valid |
| CERUXIM 750 mg powder for solution for injection or infusion | 750 mg | powder for solution for injection · Parenteral use | 10 Vial | SAR 67.10 | Generic · Prescription | MEDOCHEMIE LTD PHARMACEUTICAL INDUSTRY | Valid |
| Cefuroxime-Kotra | 750 mg | Powder for injection · Intramuscular and intravenous use | 10 Vial | SAR 67.00 | Generic · Prescription | Kotra pharma M Sdn Bhd | Valid |
| Cefuroxime-Venus | 750 mg | Powder for solution for injection/infusion · Intramuscular and intravenous use | 1 Vial | SAR 6.70 | Generic · Prescription | VENUS REMEDIES LIMITED | Valid |
| Cefuzime | 500 mg | Film-coated tablet · Oral use | 15 Blister | SAR 85.85 | Generic · Prescription | GULF PHARMACEUTICAL INDUSTIRES- JULPHAR | Valid |
| DAROXIME | 500 mg | Film-coated tablet · Oral use | 10 Blister | SAR 32.95 | Generic · Prescription | DAR ALDAWA | Valid |
| DAROXIME 250 mg film-coated tablet | 250 mg | Film-coated tablet · Oral use | 10 Blister | SAR 25.85 | Generic · Prescription | DAR ALDAWA | Valid |
| Daroxime | 500 mg | Film-coated tablet · Oral use | 14 Bottle | SAR 46.05 | Generic · Prescription | DAR Al DAWA | Valid |
| EMDITIL 500MG Film-coated TABLET | 500 mg | Film-coated tablet · Oral use | 10 Bottle | SAR 34.50 | Generic · Prescription | Med City Pharma | Valid |
| MAXIL 1500 VIAL | 1.5 g | Powder for injection · Parenteral use | 1 Vial | SAR 14.90 | Generic · Prescription | Hikma Pharmaceuticals PLC | Valid |
| MAXIL 750 VIAL | 750 mg | Powder for injection · Parenteral use | 1 Vial | SAR 7.50 | Generic · Prescription | Hikma Pharmaceuticals PLC | Valid |
| U-CEF 500MG F.C. TABLETS | 500 mg | Film-coated tablet · Oral use | 10 Bottle | SAR 52.05 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
26 more — full table
Indications — CHI Daman Drug Formulary
ACUTE PYELONEPHRITIS; ANTIBIOTIC SURGICAL PROPHYLAXIS; BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL SKIN INFECTIONS - IMPETIGO AND ECTHYMA; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; COMMUNITY ACQUIRED PNEUMONEA; HIP AND KNEE REPLACEMENT SURGERY; HOSPITAL AND VENTILATER ACQUIRED PNEUMONIA; INTRA-ABDOMINAL INFECTIONS; Pyogenic Arthritis; SINUSITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CEFUROXIME SODIUM | EQ 750MG BASE/VIAL | injectable · intramuscular, intravenous | ACS DOBFAR SPA | Prescription | 30 May 1997 |
| CEFUROXIME SODIUM | EQ 1.5GM BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 30 May 1997 |
| CEFUROXIME SODIUM | EQ 750MG BASE/VIAL | injectable · intramuscular, intravenous | HIKMA | Prescription | 9 Jan 2004 |
| CEFUROXIME SODIUM | EQ 1.5GM BASE/VIAL | injectable · injection | HIKMA | Prescription | 9 Jan 2004 |
| CEFUROXIME | 1.5G/20ML; 1.5G/100ML | injectable · injection | HIKMA | Prescription | 9 Jan 2004 |
| CEFUROXIME AXETIL | EQ 125MG BASE; EQ 250MG BASE; EQ 500MG BASE | tablet · oral | CHARTWELL RX | Prescription | 29 Jul 2005 |
| CEFUROXIME AXETIL | EQ 125MG BASE; EQ 250MG BASE; EQ 500MG BASE | tablet · oral | AUROBINDO PHARMA | Prescription | 29 Mar 2006 |
| CEFUROXIME AXETIL | EQ 125MG BASE; EQ 250MG BASE; EQ 500MG BASE | tablet · oral | ANDA REPOSITORY | Prescription | 15 Feb 2008 |
| CEFUROXIME AXETIL | EQ 250MG BASE; EQ 500MG BASE | tablet · oral | ALKEM LABS LTD | Prescription | 7 Jun 2010 |
| ZINACEF | EQ 750MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · intramuscular, intravenous | PAI HOLDINGS PHARM | Discontinued | 19 Oct 1983 |
| ZINACEF | EQ 1.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 7.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | PAI HOLDINGS PHARM | Discontinued | 19 Oct 1983 |
| KEFUROX IN PLASTIC CONTAINER | EQ 750MG BASE/VIAL | injectable · intravenous | LILLY | Discontinued | 10 Jan 1986 |
| KEFUROX IN PLASTIC CONTAINER | EQ 1.5GM BASE/VIAL | injectable · injection | LILLY | Discontinued | 10 Jan 1986 |
| KEFUROX | EQ 750MG BASE/VIAL | injectable · intramuscular, intravenous | ACS DOBFAR | Discontinued | 10 Jan 1986 |
| KEFUROX | EQ 1.5GM BASE/VIAL; EQ 7.5GM BASE/VIAL | injectable · injection | ACS DOBFAR | Discontinued | 10 Jan 1986 |
| KEFUROX | EQ 750MG BASE/VIAL | injectable · intravenous | LILLY | Discontinued | 10 Jan 1986 |
| KEFUROX | EQ 1.5GM BASE/VIAL | injectable · injection | LILLY | Discontinued | 10 Jan 1986 |
| CEFTIN | EQ 125MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 500MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | GLAXOSMITHKLINE | Discontinued | 28 Dec 1987 |
| ZINACEF IN PLASTIC CONTAINER | EQ 15MG BASE/ML; EQ 30MG BASE/ML | injectable · injection | PAI HOLDINGS PHARM | Discontinued | 28 Apr 1989 |
| CEFUROXIME SODIUM | EQ 750MG BASE/VIAL | injectable · intramuscular, intravenous | WATSON LABS INC | Discontinued | 26 Feb 1993 |
| CEFUROXIME SODIUM | EQ 1.5GM BASE/VIAL | injectable · injection | WATSON LABS INC | Discontinued | 26 Feb 1993 |
| CEFUROXIME SODIUM | EQ 7.5GM BASE/VIAL | injectable · injection | WATSON LABS INC | Discontinued | 26 Feb 1993 |
| CEFTIN | EQ 125MG BASE/5ML; EQ 250MG BASE/5ML | for suspension · oral | GLAXOSMITHKLINE | Discontinued | 30 Jun 1994 |
| CEFUROXIME SODIUM | EQ 7.5GM BASE/VIAL | injectable · injection | ACS DOBFAR SPA | Discontinued | 30 May 1997 |
| CEFUROXIME SODIUM | EQ 7.5GM BASE/VIAL | injectable · injection | TEVA PHARMS | Discontinued | 16 Apr 1998 |
18 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-CEFUROXIME | 02244393 | 250 MG | TABLET · ORAL | APOTEX INC |
| APO-CEFUROXIME | 02244394 | 500 MG | TABLET · ORAL | APOTEX INC |
| AURO-CEFUROXIME | 02344823 | 250 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-CEFUROXIME | 02344831 | 500 MG | TABLET · ORAL | AURO PHARMA INC |
| CEFTIN | 02212307 | 125 MG / 5 ML | GRANULES FOR SUSPENSION · ORAL | SANDOZ CANADA INCORPORATED |
| CEFUROXIME FOR INJECTION, USP | 02241638 | 750 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| CEFUROXIME FOR INJECTION, USP | 02241639 | 1.5 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| JAMP CEFUROXIME | 02547198 | 250 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP CEFUROXIME | 02547201 | 500 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CEFUROXIME AXETIL 250 MG TAB | $0.2798 | per EA | 23 Sep 2026 |
| US NADAC | CEFUROXIME AXETIL 500 MG TAB | $0.36555 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Cefuroxime 250mg tablets | £9.11 | 14 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.2. Watch group antibiotics · core
Second choice: Other specified prophylactic measures
Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
Safety signals and safety-related labeling changes
- US FDA 16 May 2021 ZINACEF — safety-related labeling change
Labeling sections changed: Adverse Reactions - US FDA 16 May 2021 ZINACEF IN PLASTIC CONTAINER — safety-related labeling change
Labeling sections changed: Adverse Reactions - US FDA 5 Mar 2021 CEFTIN — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations - US FDA 5 Mar 2021 CEFTIN — safety-related labeling change
Labeling sections changed: Adverse Reactions; Use in Specific Populations - US FDA 5 Dec 2020 CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER — safety-related labeling change
Labeling sections changed: Adverse Reactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.